Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Aftimos

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialElisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2024
EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across EuropeMichail Ignatiadis, Fiorita Poulakaki, Tanja Spanic, et al.
Cancers|July 27, 2024
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> 2020, <i>12</i>, 512Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Breast Cancer Research : BCR|September 11, 2020
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using <sup>18</sup>F-FES PET/CT imagingAgnes Jager, Elisabeth G E de Vries, C Willemien Menke-van der Houven van Oordt, et al.
Nature Medicine|April 20, 2022
Delivering precision oncology to patients with cancerJoaquin Mateo, Lotte Steuten, Philippe Aftimos, et al.
Cancers|February 27, 2020
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of ResistanceMohamad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Cancers|October 17, 2020
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. <i>Cancers</i> 2020, <i>12</i>, 512Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2015
Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapyEvandro de Azambuja, Lieveke Ameye, Marie Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.
BMJ Open|November 15, 2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour typesCaroline Lonez, Bikash Verma, Alain Hendlisz, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialElisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2024
EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across EuropeMichail Ignatiadis, Fiorita Poulakaki, Tanja Spanic, et al.
Cancers|July 27, 2024
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> 2020, <i>12</i>, 512Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Breast Cancer Research : BCR|September 11, 2020
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using <sup>18</sup>F-FES PET/CT imagingAgnes Jager, Elisabeth G E de Vries, C Willemien Menke-van der Houven van Oordt, et al.
Nature Medicine|April 20, 2022
Delivering precision oncology to patients with cancerJoaquin Mateo, Lotte Steuten, Philippe Aftimos, et al.
Cancers|February 27, 2020
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of ResistanceMohamad Krayem, Philippe Aftimos, Ahmad Najem, et al.
Cancers|October 17, 2020
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. <i>Cancers</i> 2020, <i>12</i>, 512Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 2015
Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapyEvandro de Azambuja, Lieveke Ameye, Marie Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.
BMJ Open|November 15, 2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour typesCaroline Lonez, Bikash Verma, Alain Hendlisz, et al.
Pageof 9